Formulation and evaluation of omeprazole tablets for duodenal ulcer

Abstract

Omeprazole pellets containing mucoadhesive tablets were developed by direct punch method. Three mucoadhesive polymers namely hydroxypropylemethylcellulose K4M, sodium carboxy methylcellulose, carbopol-934P and ethyl cellulose were used for preparation of tablets which intended for prolong action may be due to the attachment with intestinal mucosa for relief from active duodenal ulcer. Mucoadhesive tablets were coated with respective polymer and coated with Eudragit L100 to fabricate enteric coated tablets. The prepared tablets were evaluated for different physical parameters and dissolution study were performed in three dissolution mediums like 0.1N hydrochloric acid for 2h, pH 6.5 and pH 7.8 phosphate buffer solution for 12hr. Sodium carboxymethylcellulose showed above 95% release within 10 h where as carbopol-934P showed slow release about 88% to 92% over a period of 12 h. having excellent mucoadhesive strength but ethyl cellulose containing tablets showed less than 65% release. The release mechanism of all formulation was diffusion controlled confirmed from Higuchi’s plot. Thus, the present study concluded that, carbopol-934P containing mucoadhesive tablets of omeprazole pellets can be used for local action in the ulcer disease as well as for oral controlled release drug delivery.

Untitled

“…This observation clearly suggests that the drug remains in its normal form with no prominent interaction occur in drug and excipients. Figure 1 shows comparison between drug and physical mixture 14 . General Characteristic: The core tablets were white, circular, smooth surface and concave in shape.…”

Untitled

“…Compatibility Studies: Compatibility of lornoxicam with different excipients was tested using FT-IR Spectrophotometer 4 .…”

Generation and Characterization of Novel Delayed Extended Release Co-Processed Excipient With Gastric Stabilizing Activity

“…[8,9] Proton Pump Inhibitors (PPI's) are highly effective in the management of acid related diseases, including duodenal ulcer, gastric ulcer, gastro esophageal reflux disease, erosive esophagitis, hyper secretory syndromes like Zollinger-Ellison, and H.pylori infection. [11] those occurring in patients with serious underlying illness) respond better to frequent higher doses (omeprazole 40 mg once/day or more for 6 to 8 week) because chances of rebound hyper acid secretion is very high. It has been suggested that sustained release dosage form of omeprazole may prolong the drug release for extended period of time and provide better therapeutic efficacy by inhibiting the regeneration of H + /K + -ATPase for longer duration (more than 3 days) in chronic acid related disorders.…”

“…It has been suggested that sustained release dosage form of omeprazole may prolong the drug release for extended period of time and provide better therapeutic efficacy by inhibiting the regeneration of H + /K + -ATPase for longer duration (more than 3 days) in chronic acid related disorders. [11,13] In the present study, attempts have been made to develop co-processed pH dependent polymer for omeprazole drug in acidic environment as a stable delayed release tablet formulation and may give local effect in duodenal ulcer, reduced drug loss and also reduced dosing frequency due to sustained release of drug from the matrix.…”